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Abstract
Background: In facioscapulohumeral dystrophy (FSHD) muscle function is impaired and declines over time. Currently 
there is no effective treatment available to slow down this decline. We have previously reported that loss of muscle 
strength contributes to chronic fatigue through a decreased level of physical activity, while fatigue and physical 
inactivity both determine loss of societal participation. To decrease chronic fatigue, two distinctly different therapeutic 
approaches can be proposed: aerobic exercise training (AET) to improve physical capacity and cognitive behavioural 
therapy (CBT) to stimulate an active life-style yet avoiding excessive physical strain. The primary aim of the FACTS-2-
FSHD (acronym for Fitness And Cognitive behavioural TherapieS/for Fatigue and ACTivitieS in FSHD) trial is to study the 
effect of AET and CBT on the reduction of chronic fatigue as assessed with the Checklist Individual Strength subscale 
fatigue (CIS-fatigue) in patients with FSHD. Additionally, possible working mechanisms and the effects on various 
secondary outcome measures at all levels of the International Classification of Functioning, Disability and Health (ICF) 
are evaluated.
Methods/Design: A multi-centre, assessor-blinded, randomized controlled trial is conducted. A sample of 75 FSHD 
patients with severe chronic fatigue (CIS-fatigue ≥ 35) will be recruited and randomized to one of three groups: (1) AET 
+ usual care, (2) CBT + usual care or (3) usual care alone, which consists of no therapy at all or occasional (conventional) 
physical therapy. After an intervention period of 16 weeks and a follow-up of 3 months, the third (control) group will as 
yet be randomized to either AET or CBT (approximately 7 months after inclusion). Outcomes will be assessed at 
baseline, immediately post intervention and at 3 and 6 months follow up.
Discussion: The FACTS-2-FSHD study is the first theory-based randomized clinical trial which evaluates the effect and 
the maintenance of effects of AET and CBT on the reduction of chronic fatigue in patients with FSHD. The interventions 
are based on a theoretical model of chronic fatigue in patients with FSHD. The study will provide a unique set of data 
with which the relationships between outcome measures at all levels of the ICF could be assessed.
Trial registration: Dutch Trial Register, NTR1447.
Background
Facioscapulohumeral dystrophy (FSHD) is the third most
common inherited neuromuscular disorder. It is an auto-
somal dominant slowly progressive myopathy with a vari-
able age of onset, mostly in the second or third decade of
life. Its yearly incidence rate is approximately 1:20.000 [1].
The disease primarily affects the facial muscles, the mus-
cles of the shoulder girdle (most typically the scapula sta-
bilizers) and various leg muscles, while pelvic and trunk
muscles are eventually affected as well [2-4]. The pattern
of muscle weakness is often asymmetrical, and the rate
and extent of progression may vary considerably with
sudden periods of unexplained rapid disease progression.
In a small percentage of the patients, even respiratory
insufficiency may occur [5]. Only very recently, evidence
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became available that there may be a selective involve-
ment of the central nervous system as well, in terms of
decreased grey matter volume [6] and reduced intracorti-
cal inhibition [7]. Although FSHD is associated with a
partial deletion of a critical number of repetitive elements
(D4Z4) on chromosome 4q35, to date no causal gene has
been identified and no curative treatment is available
[3,8]. FSHD may eventually lead to serious disabilities of
speech, swallowing, reaching, standing and walking, even
in early adulthood. Twenty percent of the patients
become wheelchair bound. Since no cure is available,
rehabilitation is the mainstay of treatment [2,3,9].
Only recently it was shown by our group that severe
fatigue, defined as a score equal or higher than 35 on the
subscale fatigue of the Checklist Individual Strength
(CIS-fatigue), was reported by 61% of the patients with
FSHD. These severely fatigued patients had more prob-
lems with physical and social functioning as well as with
mental and general health than similar patients without a
severe fatigue. They also had more problems with con-
centration, initiating and planning [10]. As such, experi-
enced fatigue should be clearly distinguished from
muscle weakness, which is probably the most common
and characteristic symptom of FSHD [11]. In a longitudi-
nal study, we built a model of perpetuating factors for
fatigue in patients with FSHD (figure 1). It appeared that
lack of physical activity, sleep disturbances and pain all
contributed to experienced fatigue. In addition, loss of
muscle strength and pain contributed to fatigue through
a lower level of physical activity. Ultimately, experienced
fatigue and physical inactivity both contributed to the
level of societal participation [12]. Thus, theoretically, in
order to improve societal participation one should
improve muscle strength, reduce pain, optimize physical
activity and alleviate experienced fatigue. In addition,
falling appears to be a major problem among FSHD
patients. Our group was able to show that 65% of the
patients reported falling at least once a year [13]. Since
fall incidents often lead to fear of falling and avoidance
behaviour, they have a serious negative impact on physi-
cal activity and participation.
Improving muscle strength by strength training and/or
(anabolic) medication has shown not to be successful in
patients with FSHD [14]. Until now, only one trial has
investigated low-intensity aerobic exercises, indicating
that aerobic training is a safe method to increase exercise
performance [14,15]. Although, in general, physical activ-
ity does not appear harmful [16,17], more research is
needed to establish whether AET is beneficial in patients
with FSHD. Besides improving physical (aerobic) capac-
ity, it seems important to optimize physical activity and
change behaviour in daily life. Indeed, symptoms and
signs of muscle weakness and fatigue as well as the antici-
pation of a (further) decline in physical capacity may elicit
an inactive life-style, which may disproportionally affect
physical activity, fatigue and societal participation. From
this perspective, it might be beneficial to alter illness cog-
nitions and coping styles by means of CBT. However, evi-
dence for the effectiveness of CBT in patients FSHD is
not yet available.
The primary objective of the FACTS-2-FSHD trial is:
- to study the efficacy of AET and CBT for decreasing 
chronic fatigue in patients with FSHD. It is hypothe-
sized that both AET and CBT are more effective in 
decreasing fatigue than usual care, which is no ther-
apy at all or occasional (conventional) physical ther-
apy. The improvement by AET may be obtained 
through enhancement of physical (aerobic) capacity, 
whereas beneficial effects of CBT may be achieved 
through changes in daily activities and behaviour. By 
changing illness cognitions and improving coping 
style, the balance between actual behaviour and phys-
ical capacity will be optimized. Since changes 
achieved by CBT are more 'intrinsic', possible benefi-
cial effects of CBT may last longer than those of AET.
Secondary objectives of the FACTS-2-FSHD trial are:
- to evaluate the effects of AET and CBT on bodily 
functions and structures as defined by the Interna-
tional Classification of Functioning, Disability and 
Health (ICF): lower extremity muscle strength, pain, 
psychological well being, cardiovascular risk factors, 
aerobic exercise tolerance, sleeping pattern, as well as 
biomarkers in blood and urine and structural and 
metabolic muscle tissue characteristics.
- to evaluate the effects of AET and CBT on the ICF 
level of activities: physical activity in daily life, self 
perceived functional status, and fall incidence.
- to evaluate the effects of AET and CBT on the ICF 
level of participation: limitations in participation and 
autonomy and quality of life.
- to evaluate the effects of AET and CBT on environ-
mental and personal factors as defined by the ICF: 
coping style, illness cognitions, concentration prob-
lems, motivation, caregiver strain, experienced 
fatigue of the caregiver, social support and coping of 
the caregiver.
Methods
Study population
It is intended to include 75 FSHD patients, diagnosed on
both clinical and genetic grounds, aged 18 years and
older. All patients who participated in previous FSHD
studies at the Radboud University Nijmegen Medical
Centre [10,12,14,18] are approached by the primary
investigator (NV). In addition, all patients known at the
departments of Neurology and Rehabilitation of the Rad-
boud University Nijmegen Medical Centre, University
Medical Centre of Utrecht, Amsterdam University Medi-
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cal Centre or any of the affiliated rehabilitation centres
are invited to participate as well. In addition, patients
who are registered in the Dutch neuromuscular "com-
puter registry of all myopathies and polyneuropathies"
(CRAMP) database [19] and/or who are member of the
Dutch patient support organisation "vereniging spierziek-
ten Nederland" (VSN) will be invited by the primary
investigator (NV) and a member of the VSN, respectively,
to take part in the study. If the patient is willing to partic-
ipate, the primary investigator (NV) will check the inclu-
sion and exclusion criteria (table 1) and estimate the
disease severity using the Ricci score [20]. When a patient
meets all the criteria, oral and written informed consent
are obtained according to the declaration of Helsinki.
Separate consent is asked to (i) obtain blood and urine
samples, and/or (ii) undergo magnetic resonance imaging
(MRI)/spectroscopy (MRS), and/or (iii) undergo muscle
ultrasound. The study protocol was approved by the
Dutch ethical committee CCMO (Centrale commissie
mensgebonden onderzoek) and all participating centers
granted (ethical) approval to participate.
Randomization and blinding
Participants fulfilling all inclusion and exclusion criteria
are randomised to one of three groups by creating com-
puter-generated 'blocks' ensuring that the same number
of participants is allocated to each group. Experimental
group 1 (E1) receives AET and usual care for 3 times a
week during 16 weeks. Experimental group 2 (E2)
receives CBT and usual care once time a week during 16
weeks. Thereafter, both groups are followed up for 6
months. A third group (C) receives usual care only for 16
weeks and serves as a waiting list control group. After
another 3-months follow-up (i.e. 7 months after inclu-
sion), this group will as yet be randomised to either AET
or CBT for 16 weeks and followed up until 6 months later
(total time in study 17 months) (figure 2). All outcomes
are assessed by blinded and independent physical thera-
pists. At the beginning of each assessment, patients are
always instructed not to reveal their group allocation to
the blinded assessor.
Interventions
Usual care
All participants receive usual care. In the Netherlands,
patients with FSHD typically receive no therapy at all, or
occasional (conventional) physical therapy. Patients are
not restricted in any activities, but all co-interventions
are monitored throughout the study by diaries and at
every measurement.
Figure 1 Model of perpetuating factors of experienced fatigue in patients with FSHD.
Pain
Physical activityMuscle strength Experienced fatigue
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participation
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+
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Aerobic Exercise Training (AET)
The AET consists of aerobic cycling exercise on a bicycle
ergometer. The training program has a duration of 16
weeks and comprises home training twice a week and a
supervised training once a week. Training sessions con-
sist of a 30-minute aerobic exercise period with a warm-
ing-up and cooling-down period of 5 and 3 minutes,
respectively. The cardiovascular load during the training
period is individually adjusted and increased from a level
of 60% to 75% of the heart rate reserve (HRR). HRR is the
difference between the predicted maximum heart rate
and the measured resting heart rate. The HRR is equiva-
lent to the difference between the maximum and resting
maximal oxygen consumption (VO2max). Each partici-
pant is learned how to adjust the physical load to the pre-
ferred individual heart rate. Participants are supplied
with a Monark 827E bicycle ergometer, a Garmin fore-
runner 50 heart rate watch with breast belt, and a log
book with training instructions at home for the duration
of the intervention. During each training, the heart rate is
monitored continuously by the breast belt. The number
of training sessions, the total time spent on AET, possible
adverse effects and the training parameters (physical
load, heart rate) are recorded in the individual log book.
Once a week, individually supervised training is given by
trained physical therapists during one-hour sessions in
small groups in a nearby rehabilitation centre. During
these sessions, therapy compliance in the home situation
is verified by reading out the heart rate watches and
checking the log books. In addition, instructions for the
next week are provided. The (unblinded) primary investi-
gator and physician (NV) gives instructions to the physi-
cal therapists and performs integrity checks at each
treatment location.
Cognitive Behavioural Therapy (CBT)
CBT will be focused on the perpetuating factors of
fatigue as established in previous research [10,12,24] and
based on experience in clinical practice. These factors
encompass insufficient coping with the disease, dysfunc-
tional illness cognitions, catastrophizing, deregulation of
sleep, deregulation of activity, low social support and
negative social interactions (see appendix 1 for the vari-
ous modules). Because of large inter-individual differ-
ences, CBT will be adapted to the needs of each patient.
For instance, barriers to become more physically active
are explored and possibly alleviated in some patients,
whereas overactivity is reduced in others. To determine
which modules are appropriate, each perpetuating factor
is assessed with specific tests, and within each module,
the CBT approach is standardized (see appendix 1). The
precise number of sessions is dependent on the number
of modules. Each session has a duration of one hour and
is given at the most nearby participating centre by a regis-
tered cognitive behavioural therapist, especially trained
in CBT for FSHD. The therapists have been specifically
trained to use the diagnostic tests and indicate the differ-
ent modules and are regularly supervised by one of the
investigators (GB).
Compliance and attrition
Therapy compliance is assessed by recording the number
of treatment sessions (AET and CBT). For the partici-
pants randomized to AET, the total time spent on the
bicycle ergometer at home is recorded as well. When
applicable, participants are asked for their reasons for
poor compliance. In the case of therapy drop out, patients
are asked for the reason of non compliance and are stim-
Table 1: Inclusion and exclusion criteria
Inclusion criteria
(1) age 18 years and older
(2) suffering from severe fatigue (CIS-fatigue ≥ 35) [21]
(3) ability to walk independently (ankle-foot orthoses and canes 
are accepted)
(4) being able to exercise on a bicycle ergometer
(5) being able to complete either type of intervention
Exclusion criteria
(1) cognitive impairment
(2) insufficient mastery of the Dutch language
(3) neurological or orthopedic co-morbidity interfering with the 
interventions or possibly influencing outcomes
(4) pregnancy
(5) use of psychotropic drugs (except simple sleeping 
medication)
(6) severe cardiopulmonary disease (chest pain, arrhythmia, 
pacemaker, cardiac surgery, severe exertional dyspnea, 
emphysema)
(7) epileptic seizures
(8) poorly regulated diabetes mellitus or hypertension
(9) clinical depression, as diagnosed with the Beck Depression 
Inventory for primary care (BDI-PC) [22,23]
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Figure 2 Study design T.
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ulated to continue participation in the assessments until
the last follow-up.
Outcome assessment
Outcome measures are listed in table 2. The primary out-
come measure is fatigue severity as assessed with the
CIS-fatigue [21]. Secondary outcome measures are cate-
gorized according to the different ICF levels [25]. Out-
come measurements are obtained at the Radboud
University Nijmegen Medical Centre at the start of the
study period (T0), immediately after the intervention
period of 16 weeks (T1) and after 3 (T2) and 6 months of
follow-up (T3). Observers of the secondary outcome
measurements are experienced physical therapists
blinded for treatment allocation. At the first measure-
ment (T0), demographic data is obtained by the primary
investigator and physician (NV), as well as a general and
FSHD related medical history, anthropometric measures
(diastolic and systolic blood pressure in mm, resting pulse
rate in beats per minute and auscultation of heart and
lungs), to verify eligibility. The baseline (T0) and post
treatment (T1) visits consist of muscle strength testing of
the thigh and aerobic exercise tolerance testing. Partici-
pants are asked to complete the questionnaires and to
wear the actometer for 12 consecutive days. An actome-
ter is a motion sensing device that can register and quan-
tify human physical activity and has to be worn at the
ankle [26,27]. Blood and urine analyses and MRI, MRS
and ultrasound measurements of the thigh muscles are
performed. Follow-up measurements (T2 and T3) consist
of muscle strength testing of the thigh, aerobic exercise
tolerance testing, questionnaires are completed and the
actometer is provided.
At the level of bodily functions and structures, patients
are asked to give separate consent for several 'invasive'
assessments at baseline and after the intervention period.
Blood and urine samples are collected by experienced
nurses and will be explored by nuclear magnetic reso-
nance (NMR) for possible biomarkers of disease and
response to the interventions. Ultrasound measurements
of the thigh muscles are made by an experienced ultra-
sound professional, blinded for the treatment allocation,
and analyzed for muscle thickness and echo intensity. In
addition, Magnetic Resonance Imaging (MRI) and 31P
and proton (1H) Magnetic Resonance Spectroscopy
(MRS) are performed by trained professionals, blinded
for the assignment to the intervention. It has been shown
that in vivo MRS is able to produce spectra of multiple
metabolites simultaneously and is well suited to study
energy metabolism in patients with muscular dystrophies
[28,29]. The MR examinations start with T1 and T2
weighted images of the thigh for detailed structural anal-
ysis. Muscle involvement is specifically assessed by the
presence of fatty infiltration on T1 weighted MR images.
1H MRS is used to assess muscle specific creatine as well
as extramyocellular lipids and intramyocellular lipids lev-
els, whereas 31P MRS is applied to get information about
tissue pH and the level of high energy phosphates present
in the different thigh muscles.
Adverse events
An adverse event is defined as any undesirable experience
or outcome. Specially assigned site investigators are
instructed to report all adverse events immediately to the
primary investigator (NV) and to evaluate each event for
its date of onset, possible relation to the interventions
(based on clinical judgment), possible treatment and
course in time. In addition, adverse events can be
reported by the participants directly to the primary inves-
tigator and physician (NV). All adverse events reported
will be carefully monitored and registered until they have
abated or a stable situation has been reached.
Statistical Analysis
Generalized estimated equations analysis will be used to
investigate differences in the effects on primary and sec-
ondary outcome measures between the study groups and
to investigate the influence of possible effect modifiers.
When necessary, analyses will be adjusted for group dif-
ferences in fatigue severity and physical activity at base-
line. Data will be analyzed according to the intention-to-
treat principle.
Power
In order to detect a 10% group difference (E1 and E2 ver-
sus C) in change in fatigue severity between the start and
the end of the intervention period (assuming difference in
standard deviation between the start and the end of the
intervention (SDdif ) = 10%, α = .05, β = .80), 20 partici-
pants per group are required. With an expected drop-out
rate of maximally 25%, 25 participants will be recruited in
each group (n = 75).
Discussion
To the best of our knowledge, the FACTS-2-FSHD study
is the first randomized clinical trial which evaluates the
effect of AET and CBT on the reduction of chronic
fatigue in patients with FSHD.
This study has several strengths. First, the selected
interventions are based on a theoretical model of chronic
fatigue in patients with FSHD [12] and are compared with
usual care in a randomized design. Until now, only one
randomized controlled trial has been conducted that
could not establish a beneficial effect of muscle strength
training compared to no training in FSHD [14,18]. In
addition, one trial has been conducted that investigated
low-intensity aerobic exercises in FSHD. Although this
latter study reported improved maximal oxygen uptake
and workload as a result of training, this was an uncon-
trolled and unblinded trial of only 8 patients [15]. The
majority of the training studies in patients with muscle
disorders did not include a (no-training) control group or
Voet et al. BMC Neurology 2010, 10:56
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Table 2: Outcome measures and tests
Tests
Primary outcome measure
Fatigue severity Checklist Individual Strength (CIS subscale fatigue) [30]
Secondary outcome measures
ICF: bodily funtions
Aerobic exercise tolerance Maximal oxygen consumption (VO2 max) using the Astrand protocol[31]
6-minutes walking test [32]
Resting heart rate
Muscle strength of quadriceps, Quantitative Muscle Assessment using fixed myometry testing
hamstrings and tibialis anterior system (QMA) [18]
muscles
Cardiovascular risk factors Blood pressure*
Abdominal circumference
Weight/Body Mass Index (BMI)
Percentage body fat
Visual Analogue Scale (VAS) [33]
Pain Daily Observed Pain (during a period of 2 weeks) [27,34]
Psychological well-being and Brief Symptom Inventory (BSI) [35]
sleeping pattern
Metabolic biomarkers Blood and urine analyses for creatine, glucose, creatine kinase,
sodium, potassium, calcium, phosphorus, ureum, ALAT, ASAT,
gamma-GT, bilirubine, AF and LDH***
Structural and metabolic muscle 
characteristics
T1 MRI, T2 MRI, 31P and 1H MRS analysis of muscle specific creatine, extramyocellular lipids, 
intramyocellular lipids, levels and phosphometabolites in thigh muscles; ultrasound of thigh 
muscles
ICF: activities
Physical activity in daily life Actometer, a motion sensing device (during a period of 2 weeks)
[26,27]
Daily Observed Spontaneous physical activity (during a period of 2 weeks) [27,34].
Checklist Individual Strength (CIS subscale physical activity) [30]
Self perceived functional status Sickness Impact Profile (SIP subscales mobility control and mobility range, social behavior) [36]
ICF: participation
Limitations in participation and 
autonomy Quality of life Fall incidence
The Impact on Participation and Autonomy Questionnaire (IPAQ)[37]
36-Item Short-Form Health Survey (SF-36) [38]
Telephone computer (weekly calls)**
ICF: personal factors
Coping Coping Inventory for Stressful Situation (CISS) [30]
ALCOS-16 [39]
Illness cognitions Ziekte cognitie lijst (ZCL) [40]
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used healthy subjects as controls. In addition, data are
often presented for mixed groups of muscle disorders
[17]. Second, the proposed study uses a broad arsenal of
secondary outcome measures at all levels of the ICF,
including 'invasive' measurements of possible biomarkers
in blood and urine as well as measurements of structural
and metabolic muscle characteristics. This approach will
provide a unique set of data with which it should be pos-
sible to accurately assess the relationships between dis-
ease characteristics, loss of bodily functions, activity
limitations and restrictions in societal participation in
patients with FSHD. Third, all patients will be followed
up until 6 months after the interventions, which will not
only provide information about the maintenance of
effects, but also about any long-term adverse events.
A limitation of this study is that the sample size calcula-
tion was based on detection of a 10% difference between
the intervention groups and the control group, presum-
ing more or less equal effect sizes of AET and CBT.
Detecting more subtle differences in the effectiveness
between both interventions would require a much larger
sample size. In the Netherlands alone, such a trial would
not be feasible.
In conclusion, the FACTS-2-FSHD study will increase
our insight into the effectiveness of aerobic exercise train-
ing and cognitive behavioural therapy to reduce chronic
fatigue and to optimize physical activity and capacity in
patients with FSHD. A successful outcome of this study
has the potential to change existing (inter)national guide-
lines for physical training and to improve the quality of
life in patients with FSHD.
Appendix 1 Different modules of Cognitive 
Behavioural Therapy
Perpetuating factors: insufficient coping with the disease
Insufficient coping with the disease is assessed with the
Impact of event Scale [43,44]. A participant can continue
to be occupied with the period of being diagnosed with
FSHD. By means of talking or writing about this experi-
ence (which can be referred to as 'exposure'), the partici-
pant will acquire better coping skills. Fear of progression
is assessed with a questionnaire especially designed for
FSHD. The therapist helps the participant to formulate
explicit words to describe the thoughts of fear of progres-
sion. These thoughts are challenged against reality (real-
ity testing). In this way, daily unhelpful thoughts about
the disease progression are reduced and put into perspec-
tive.
Perpetuating factors: dysfunctional cognitions regarding 
fatigue, activity and other symptoms
Dysfunctional cognitions relate to a variety of ideas,
including a participant's idea of lack of control over
symptoms, and dysfunctional cognitions about symp-
toms, such as catastrophizing. The sense of control in
relation to fatigue complaints will be assessed with the
self-efficacy scale [34,45].
Perpetuating factors: catastrophizing
Catastrophizing will be assessed with the Jacobsen
Fatigue Catastrophizing Scale [46]. These cognitions are
disputed and more helpful ways of thinking are taught.
Perpetuating factors: deregulation of sleep
Deregulation of sleep is based on self-report in a sleep
diary [47]. An irregular sleep-wake rhythm can perpetu-
ate fatigue. To restore the biologic rhythm, participants
are encouraged to adhere to fixed bedtimes and wake-up
times and discouraged from sleeping during the day, or
they are helped with adapting fixed rest period(s).
Perpetuating factors: deregulation of activity
Deregulation of activity is based on activity (stepping)
monitoring using an actometer and a physical activity
questionnaire (Physical Activity Scale for Individuals with
Concentration problems Checklist Individual Strength (CIS subscale concentration) [21]
Motivation Checklist Individual Strength (CIS subscale motivation)[21]
ICF: environmental factors
Caregiver strain Caregiver Strain Index of partner/caregiver (CSI) [41]
Experienced fatigue of patient Checklist Individual Strength (CIS subscale fatigue, filled in by
from perspective of relative. relative about patient) [21]
Experienced fatigue of partner. Checklist Individual Strength (CIS subscale fatigue, filled in by relative about him/herself) [21]
Social support Sociale steunlijst-subschaal discrepantie (SSL-D verkort) [42]
Coping of partner Coping Inventory for Stressful Situations (CISS) [30]
*Measured only at inclusion. **Participants will be called weekly throughout the study by a telephone-computer to obtain fall incidence; in 
the case of fall incident(s), a subsequent telephone interview is held to obtain information about the cause and circumstances of falling, fall 
direction, possible injury and ability to get up from the floor. ***In all groups, three extra urine samples will be obtained at week 4, 8 and 12 
of the intervention period.
Table 2: Outcome measures and tests (Continued)
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Physical Disabilities [44,48]). Some patients experience
fluctuating periods of activity with subsequent periods of
rest during a longer period. Others avoid activity because
they are concerned that activity increases fatigue; conse-
quently, they are physically inactive. For patients with
fluctuating activity levels, a base level should be estab-
lished by alternating rest and activities to prevent bursts
of activity. Once the participant has set a base level, the
physical activity program is started, usually twice a day,
starting with 5 to 10 minutes of an activity such as walk-
ing or cycling. The activity is increased by 1 minute a day
each time the activity is performed (ending at a maxi-
mum of 2 times 60 minutes minutes per day). The inac-
tive participant will start the activity program
immediately. Gradually, physical activities are replaced by
other activities.
Perpetuating factors: low social support and negative social 
interactions
Low social support and negative social interactions are
based on the discrepancy subscale of the Social Support
List [49]. If a participant still has unrealistic expectations
of others or perceives a discrepancy between actual sup-
port and desired support, the therapist helps to install
more realistic expectations toward the participant's social
support group. The partner or caregiver will be included
in this treatment module.
Abbreviations
1H: proton; 31P: phosphorous; AET: aerobic exercise therapy; CBT: cognitive
behavioural therapy; CCMO: Centrale commissie mensgebonden onderzoek;
CIS: Checklist individual strength; CRAMP: computer registry of all myopathies
and polyneuropathies; E1: experimental group 1; E2: experimental group 2;
FACTS-2-FSHD: acronym for Fitness And Cognitive behavioural TherapieS/for
Fatigue and ACTivitieS in FSHD; FSHD: facioscapulohumeral dystrophy; HRR:
heart rate reserve; ICF: International Classification of Functioning, Disability and
Health; MRI: magnetic resonance imaging; MRS: magnetic resonance spectros-
copy; NMR: nuclear magnetic resonance; VO2max: maximal oxygen consump-
tion; VSN: Vereniging spierziekten Nederland.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
NV is primary investigator and responsible for data collection and analysis and
for drafting the manuscript. AG, BvE, GB, and GP designed and supervised the
study. AG and BvE obtained funding for the study. All authors helped in finaliz-
ing the manuscript.
Acknowledgements
This study is funded by the Prinses Beatrix Fonds (PBF) (The Dutch Public Fund 
for Neuromuscular and Movement Disorders), the Netherlands Organization 
for Health Research and Development (ID: ZonMW 89000003) and by the FSHD 
Global Research Foundation.
Author Details
1Nijmegen Centre for Evidence Based Practice; Department of Rehabilitation, 
Radboud University Nijmegen Medical Centre; Nijmegen, The Netherlands, 
2Expert Centre Chronic Fatigue, Radboud University Nijmegen Medical Centre; 
Nijmegen, The Netherlands and 3Department of Neurology, Donders Centre 
for Neuroscience; Radboud University Nijmegen Medical Centre; Nijmegen, 
The Netherlands
References
1. Kissel JT: Facioscapulohumeral dystrophy.  Semin Neurol 1999, 19:35-43.
2. Padberg GW, Lunt PW, Koch M, Fardeau M: Diagnostic criteria for 
facioscapulohumeral muscular dystrophy.  Neuromuscul Disord 1991, 
1:231-234.
3. Tawil R, van der Maarel SM: Facioscapulohumeral muscular dystrophy.  
Muscle Nerve 2006, 34:1-15.
4. Padberg GW, van Engelen BG: Facioscapulohumeral muscular 
dystrophy.  Curr Opin Neurol 2009, 22:539-542.
5. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, 
Padberg GW: Ventilatory support in facioscapulohumeral muscular 
dystrophy.  Neurology 2004, 63:176-178.
6. Quarantelli M, Lanzillo R, Del VW, Mollica C, Prinster A, Iadicicco L, Iodice V, 
Santoro L: Modifications of brain tissue volumes in 
facioscapulohumeral dystrophy.  Neuroimage 2006, 32:1237-1242.
7. Di Lazzaro V, Oliviero A, Tonali PA, Felicetti L, De Marco MB, Saturno E, 
Pilato F, Pescatori M: Dileone M, Pasqualetti P, Ricci E: Changes in motor 
cortex excitability in facioscapulohumeral muscular dystrophy.  
Neuromuscul Disord 2004, 14:39-45.
8. van der Maarel SM, Frants RR, Padberg GW: Facioscapulohumeral 
muscular dystrophy.  Biochim Biophys Acta 2007, 1772:186-194.
9. Lunt PW, Harper PS: Genetic counselling in facioscapulohumeral 
muscular dystrophy.  J Med Genet 1991, 28:655-664.
10. Kalkman JS, Schillings ML, van der Werf SP, Padberg GW, Zwarts MJ, van 
Engelen BG, Bleijenberg G: Experienced fatigue in facioscapulohumeral 
dystrophy, myotonic dystrophy, and HMSN-I.  J Neurol Neurosurg 
Psychiatry 2005, 76:1406-1409.
11. Engel AG, Franzini-Armstrong C: Myology.  2004.
12. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G: The 
development of a model of fatigue in neuromuscular disorders: a 
longitudinal study.  J Psychosom Res 2007, 62:571-579.
13. Horlings CG, Munneke M, Bickerstaffe A, Laverman L, Allum JH, Padberg 
GW, Bloem BR, van Engelen BG: Epidemiology and pathophysiology of 
falls in facioscapulohumeral disease.  J Neurol Neurosurg Psychiatry 2009, 
80:1357-1363.
14. van der Kooi EL, Kalkman JS, Lindeman E, Hendriks JC, van Engelen BG, 
Bleijenberg G, Padberg GW: Effects of training and albuterol on pain and 
fatigue in facioscapulohumeral muscular dystrophy.  J Neurol 2007, 
254:931-940.
15. Olsen DB, Orngreen MC, Vissing J: Aerobic training improves exercise 
performance in facioscapulohumeral muscular dystrophy.  Neurology 
2005, 64:1064-1066.
16. Cup EH, Pieterse AJ, Ten Broek-Pastoor JM, Munneke M, van Engelen BG, 
Hendricks HT, van der Wilt GJ, Oostendorp RA: Exercise therapy and 
other types of physical therapy for patients with neuromuscular 
diseases: a systematic review.  Arch Phys Med Rehabil 2007, 88:1452-1464.
17. Voet NB, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, Geurts 
AC: Strength training and aerobic exercise training for muscle disease.  
Cochrane Database Syst Rev 2010:CD003907.
18. van der Kooi EL, Vogels OJ, van Asseldonk RJ, Lindeman E, Hendriks JC, 
Wohlgemuth M, van der Maarel SM, Padberg GW: Strength training and 
albuterol in facioscapulohumeral muscular dystrophy.  Neurology 2004, 
63:702-708.
19. Van Engelen BG, van VH, Van Doorn PA, Faber CG, van der Hoeven JH, 
Janssen NG, Notermans NC, van Schaik I, Visser LH, Verschuuren JJ: The 
Dutch neuromuscular database CRAMP (Computer Registry of All 
Myopathies and Polyneuropathies): development and preliminary 
data.  Neuromuscul Disord 2007, 17:33-37.
20. Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, Piazzo N, 
Servidei S, Vigneti E, Pasceri V, Silvestri G, Mirabella M, Mangiola F, Tonali P, 
Felicetti L: Progress in the molecular diagnosis of facioscapulohumeral 
muscular dystrophy and correlation between the number of KpnI 
repeats at the 4q35 locus and clinical phenotype.  Ann Neurol 1999, 
45:751-757.
21. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, 
Bleijenberg G: Dimensional assessment of chronic fatigue syndrome.  J 
Psychosom Res 1994, 38:383-392.
Received: 15 June 2010 Accepted: 30 June 2010 
Published: 30 June 2010
This article is available from: http://www.biomedcentral.com/1471-2377/10/56© 2010 Voet et l; licensee BioMed Central Ltd. is an Op n Access article distributed under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neurology 2010, 10:56
Voet et al. BMC Neurology 2010, 10:56
http://www.biomedcentral.com/1471-2377/10/56
Page 10 of 10
22. Arnau RC, Meagher MW, Norris MP, Bramson R: Psychometric evaluation 
of the Beck Depression Inventory-II with primary care medical 
patients.  Health Psychol 2001, 20:112-119.
23. Beck AT, Guth D, Steer RA, Ball R: Screening for major depression 
disorders in medical inpatients with the Beck Depression Inventory for 
Primary Care.  Behav Res Ther 1997, 35:785-791.
24. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G: 
Influence of relatives on fatigue experienced by patients with 
facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I.  Eur 
Neurol 2006, 56:24-30.
25. WHO: International Classification of Functioning, Disability and Health 
(ICF).  Geneva 2001.
26. van der Werf SP, Prins JB, Vercoulen JH, van der Meer JW, Bleijenberg G: 
Identifying physical activity patterns in chronic fatigue syndrome 
using actigraphic assessment.  J Psychosom Res 2000, 49:373-379.
27. Vercoulen JH, Bazelmans E, Swanink CM, Fennis JF, Galama JM, Jongen PJ, 
Hommes O, van der Meer JW, Bleijenberg G: Physical activity in chronic 
fatigue syndrome: assessment and its role in fatigue.  J Psychiatr Res 
1997, 31:661-673.
28. Argov Z, Lofberg M, Arnold DL: Insights into muscle diseases gained by 
phosphorus magnetic resonance spectroscopy.  Muscle Nerve 2000, 
23:1316-1334.
29. Kan HE, Scheenen TW, Wohlgemuth M, Klomp DW, van Loosbroek-
Wagenmans I, Padberg GW, Heerschap A: Quantitative MR imaging of 
individual muscle involvement in facioscapulohumeral muscular 
dystrophy.  Neuromuscul Disord 2009, 19:357-362.
30. Endler NS, Parker JD: Multidimensional assessment of coping: a critical 
evaluation.  J Pers Soc Psychol 1990, 58:844-854.
31. Astrand PO, Ryhming I: A normogram for calculation for aerobic 
capacity (physical fitness) from pulse rate during sub-maximal work.  J 
Appl Physiol 1954:218-222.
32. Enright PL: The six-minute walk test.  Respir Care 2003, 48:783-785.
33. Folstein MF, Luria R: Reliability, validity, and clinical application of the 
Visual Analogue Mood Scale.  Psychol Med 1973, 3:479-486.
34. Vercoulen JH, Hommes OR, Swanink CM, Jongen PJ, Fennis JF, Galama JM, 
van der Meer JW, Bleijenberg G: The measurement of fatigue in patients 
with multiple sclerosis. A multidimensional comparison with patients 
with chronic fatigue syndrome and healthy subjects.  Arch Neurol 1996, 
53:642-649.
35. Derogatis LR, Melisaratos N: The Brief Symptom Inventory: an 
introductory report.  Psychol Med 1983, 13:595-605.
36. Jacobs HM, Luttik A, Touw-Otten FW, de Melker RA: [The sickness impact 
profile; results of an evaluation study of the Dutch version].  Ned 
Tijdschr Geneeskd 1990, 134:1950-1954.
37. Cardol M, de Haan RJ, van den Bos GA, de Jong BA, de G I: The 
development of a handicap assessment questionnaire: the Impact on 
Participation and Autonomy (IPA).  Clin Rehabil 1999, 13:411-419.
38. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, 
Sprangers MA, te Velde A, Verrips E: Translation, validation, and norming 
of the Dutch language version of the SF-36 Health Survey in 
community and chronic disease populations.  J Clin Epidemiol 1998, 
51:1055-1068.
39. Bosscher RJ, Smit JH: Confirmatory factor analysis of the General Self-
Efficacy Scale.  Behav Res Ther 1998, 36:339-343.
40. Evers AW, Kraaimaat FW, van LW, Jongen PJ, Jacobs JW, Bijlsma JW: 
Beyond unfavorable thinking: the illness cognition questionnaire for 
chronic diseases.  J Consult Clin Psychol 2001, 69:1026-1036.
41. Post MW, Festen H, van dP, Visser-Meily JM: Reproducibility of the 
Caregiver Strain Index and the Caregiver Reaction Assessment in 
partners of stroke patients living in the Dutch community.  Clin Rehabil 
2007, 21:1050-1055.
42. Van Sonderen EL: Sociale Steun Lijst Interacties (SSL-I) en Sociale Steun 
Lijst Discrepanties (SSL-D).  Noordelijk centrum voor 
gezondheidsvraagstukken 1993.
43. Creamer M, Bell R, Failla S: Psychometric properties of the Impact of 
Event Scale - Revised.  Behav Res Ther 2003, 41:1489-1496.
44. van der Ploeg E, Mooren TT, Kleber RJ, van d V, Brom D: Construct 
validation of the Dutch version of the impact of event scale.  Psychol 
Assess 2004, 16:16-26.
45. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, 
van der Wilt GJ, Spinhoven P, van der Meer JW: Cognitive behaviour 
therapy for chronic fatigue syndrome: a multicentre randomised 
controlled trial.  Lancet 2001, 357:841-847.
46. Andrykowski MA, Schmidt JE, Salsman JM, Beacham AO, Jacobsen PB: Use 
of a case definition approach to identify cancer-related fatigue in 
women undergoing adjuvant therapy for breast cancer.  J Clin Oncol 
2005, 23:6613-6622.
47. Servaes P, Verhagen C, Bleijenberg G: Fatigue in cancer patients during 
and after treatment: prevalence, correlates and interventions.  Eur J 
Cancer 2002, 38:27-43.
48. Washburn RA, Zhu W, McAuley E, Frogley M, Figoni SF: The physical 
activity scale for individuals with physical disabilities: development 
and evaluation.  Arch Phys Med Rehabil 2002, 83:193-200.
49. Ormel J, Kempen GI, Penninx BW, Brilman EI, Beekman AT, van SE: Chronic 
medical conditions and mental health in older people: disability and 
psychosocial resources mediate specific mental health effects.  Psychol 
Med 1997, 27:1065-1077.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/10/56/prepub
doi: 10.1186/1471-2377-10-56
Cite this article as: Voet et al., Effect of aerobic exercise training and cogni-
tive behavioural therapy on reduction of chronic fatigue in patients with 
facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial BMC 
Neurology 2010, 10:56
